we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.
Company profile
Ticker
ICPT
Exchange
Website
CEO
Mark E. Pruzanski
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
INTERCEPT PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
Intercept Pharma Europe Ltd. ...
IRS number
223868459
ICPT stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
20 Nov 23
EFFECT
Notice of effectiveness
15 Nov 23
EFFECT
Notice of effectiveness
15 Nov 23
EFFECT
Notice of effectiveness
15 Nov 23
8-K
Entry into a Material Definitive Agreement
8 Nov 23
POS AM
Prospectus update (post-effective amendment)
8 Nov 23
POS AM
Prospectus update (post-effective amendment)
8 Nov 23
POS AM
Prospectus update (post-effective amendment)
8 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
8 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
8 Nov 23
Transcripts
ICPT
Earnings call transcript
2023 Q2
2 Aug 23
ICPT
Earnings call transcript
2023 Q1
27 Apr 23
ICPT
Earnings call transcript
2022 Q4
2 Mar 23
ICPT
Earnings call transcript
2022 Q3
1 Nov 22
ICPT
Earnings call transcript
2022 Q2
3 Aug 22
ICPT
Earnings call transcript
2022 Q1
6 May 22
ICPT
Earnings call transcript
2021 Q4
2 Mar 22
ICPT
Earnings call transcript
2021 Q3
3 Nov 21
ICPT
Earnings call transcript
2021 Q2
29 Jul 21
ICPT
Earnings call transcript
2021 Q1
6 May 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 103.66 mm | 103.66 mm | 103.66 mm | 103.66 mm | 103.66 mm | 103.66 mm |
Cash burn (monthly) | 11.24 mm | 1.38 mm | 1.54 mm | 5.19 mm | (no burn) | 5.25 mm |
Cash used (since last report) | 76.40 mm | 9.36 mm | 10.47 mm | 35.29 mm | n/a | 35.71 mm |
Cash remaining | 27.25 mm | 94.29 mm | 93.19 mm | 68.36 mm | n/a | 67.94 mm |
Runway (months of cash) | 2.4 | 68.5 | 60.5 | 13.2 | n/a | 12.9 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 156 |
Opened positions | 54 |
Closed positions | 29 |
Increased positions | 45 |
Reduced positions | 37 |
13F shares | Current |
---|---|
Total value | 717.57 bn |
Total shares | 43.01 mm |
Total puts | 2.33 mm |
Total calls | 835.60 k |
Total put/call ratio | 2.8 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 4.21 mm | $78.11 bn |
Genextra S.p.A. | 4.00 mm | $0.00 |
STT State Street | 3.20 mm | $59.29 bn |
UBS UBS Group AG - Registered Shares | 3.00 mm | $55.60 bn |
Magnetar Financial | 2.41 mm | $44.63 bn |
Alpine Associates Management | 2.20 mm | $40.85 bn |
Deerfield Management | 2.08 mm | $38.52 bn |
Vanguard | 2.07 mm | $38.40 bn |
JEF Jefferies Financial | 2.00 mm | $37.08 bn |
Alliancebernstein | 1.54 mm | $28.61 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Nov 23 | Saik Andrew | Common Stock | Sale back to company | Dispose D | No | No | 19 | 45,244 | 859.64 k | 0 |
8 Nov 23 | Saik Andrew | Common Stock | Dispose U | No | No | 19 | 23,021 | 437.40 k | 0 | |
8 Nov 23 | Saik Andrew | Option to Purchase Common Stock Common Stock | Sale back to company | Dispose D | No | No | 20.84 | 72,540 | 1.51 mm | 0 |
8 Nov 23 | Saik Andrew | Option to Purchase Common Stock Common Stock | Sale back to company | Dispose D | No | No | 18.4 | 24,000 | 441.60 k | 0 |
8 Nov 23 | Saik Andrew | Option to Purchase Common Stock Common Stock | Sale back to company | Dispose D | No | No | 14.44 | 17,600 | 254.14 k | 0 |
8 Nov 23 | Pruzanski Mark | Common Stock | Dispose U | No | No | 19 | 618,894 | 11.76 mm | 0 | |
8 Nov 23 | Pruzanski Mark | Option to Purchase Common Stock Common Stock | Sale back to company | Dispose D | No | No | 99.66 | 17,700 | 1.76 mm | 0 |
8 Nov 23 | Pruzanski Mark | Option to Purchase Common Stock Common Stock | Sale back to company | Dispose D | No | No | 110.8 | 12,811 | 1.42 mm | 0 |
8 Nov 23 | Pruzanski Mark | Option to Purchase Common Stock Common Stock | Sale back to company | Dispose D | No | No | 110.8 | 889 | 98.50 k | 0 |
8 Nov 23 | Pruzanski Mark | Option to Purchase Common Stock Common Stock | Sale back to company | Dispose D | No | No | 58.74 | 45,293 | 2.66 mm | 0 |